Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AZD1656
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Sarborg Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Conduit Progresses Phase II of its AI Initiative with Sarborg
Details : AZD1656 is a glucokinase activator small molecule drug candidate, which is currently being evaluated for the treatment of patients with lupus nephritis.
Product Name : AZD1656
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : AZD1656
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Sarborg Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AZD1656
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Conduit Pharma, Charles River Partner on Systemic Lupus Erythematosus Model
Details : Conduit will leverage Charles River’s expertise in immunology and preclinical research to help in development of AZD1656 for Lupus Nephritis.
Product Name : AZD1656
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 13, 2025
Lead Product(s) : AZD1656
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : AZD1656
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Conduit Pharma Selects Initial Indications for Autoimmune Disorder Candidate
Details : AZD1656, a HK-4 glucokinase activator, is now being repurposed by Conduit for for the treatment of systemic lupus erythematosus (including lupus nephritis) and ANCA-associated vasculitis.
Product Name : AZD1656
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 08, 2024
Lead Product(s) : AZD1656
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AZD5904
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Murphy Canyon Acquisition
Deal Size : Undisclosed
Deal Type : Merger
Details : The combined company will accelerate development of Conduit’s autoimmune disease and idiopathic male infertility pipeline, including AZD5904, a potent orally bioavailable MPO inhibitor.
Product Name : AZD5904
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 22, 2023
Lead Product(s) : AZD5904
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Murphy Canyon Acquisition
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : AZD5904
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Murphy Canyon Acquisition Corp.
Deal Size : $27.0 million
Deal Type : Private Placement
Details : AZD5904 is a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Product Name : AZD5904
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 11, 2022
Lead Product(s) : AZD5904
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Murphy Canyon Acquisition Corp.
Deal Size : $27.0 million
Deal Type : Private Placement